[Pharmacological treatment of Rett syndrome improves breathing and survival in a mouse model].
Roux
Jean-Christophe
JC
Villard
Laurent
L
D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001933:Brain Stem / Q000473:pathology / Q000503:physiopathology; D002478:Cells, Cultured / Q000187:drug effects / Q000378:metabolism; D003891:Desipramine / Q000494:pharmacology / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D051783:Methyl-CpG-Binding Protein 2 / Q000172:deficiency / Q000235:genetics / Q000502:physiology; D051379:Mice; D018345:Mice, Knockout; D009419:Nerve Tissue Proteins / Q000172:deficiency; D009474:Neurons / Q000201:enzymology / Q000473:pathology; D009638:Norepinephrine / Q000172:deficiency / Q000502:physiology; D012120:Respiration Disorders / Q000188:drug therapy* / Q000209:etiology; D015518:Rett Syndrome / Q000150:complications / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D013572:Synaptic Vesicles / Q000187:drug effects / Q000378:metabolism; D014446:Tyrosine 3-Monooxygenase / Q000172:deficiency
D018759:Adrenergic Uptake Inhibitors; C497392:MECP2 protein, human; C497393:Mecp2 protein, mouse; D051783:Methyl-CpG-Binding Protein 2; D009419:Nerve Tissue Proteins; D014446:Tyrosine 3-Monooxygenase; D003891:Desipramine; D009638:Norepinephrine